Fig. 3
From: KRAS is a molecular determinant of platinum responsiveness in glioblastoma
Sensitivity to cisplatin in KRAS HVR-mutants. Panel A—Cisplatin-induced apoptosis assayed by (Terminal deoxynucleotidyl transferase dUTP nick end labeling) TUNEL is shown in cells overexpressing plasmids coding for oncogenic KRAS carboxyl-terminal hypervariable region (HVR)-mutants KRAS-G12V, KRAS-G12V-C185A, KRAS-G12V-C185A-K177E and HRASL61S186. Histogram shows apoptotic cell percentage analysis assayed by TUNEL. Panel B 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay at increasing doses of cisplatin (3,3 µM; 6,6 µM; 16,6 µM in U87MG and U251MG. The cells were treated with MTT after 48 h from cisplatin (CDDP) administration and cell viability is expressed as percentage on the control (untreated cells). Values are expressed as mean ± s.e.m. Differences between treatments were tested for statistical significance using Student’s matched pairs t-test (*P < 0.0001 compared to untreated sample)